Compound Collection: Off-Target Agonism in a KRAS Program, an IL-1B Antagonist, and 40 More Molecules
Other articles you may be interested in
Key Clinical Compound Updates from August 2024
Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.
Patent Highlights: Allosteric AR Modulators, Glycogen Synthase Inhibitors, and More
This article highlights million-dollar molecules that were recently in the news with related patent applications that give clues to their structures and properties. This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, brain-penetrant HER2 and ROCK2 inhibitors, and MDM2 degraders.
May 2024 Molecule Roundup
To select May’s Molecules of the Month, our team evaluated hundreds of molecules from thousands of papers, press releases, conference presentations, and other materials. Check out our curated roundup of more than 60 additional molecules below that caught our interest from May, including highlights of some of our favorites, and perspectives on why these are molecules to watch.
June 2024 News Roundup: FDA Approvals, Major Deals, Obesity Research Advances, and More
In June, we saw several FDA approvals for treatments targeting primary biliary cholangitis and COPD. The industry witnessed multibillion- and multimillion-dollar deals across various therapeutic areas. Advances were made in obesity therapeutics, with novel targets and clinical readouts for GLP-1 agonists and NLRP3 inhibitors. Alkermes and Takeda reported results for OX2R agonists in narcolepsy, while an antimalarial drug showed promise in PCOS. Despite these advancements, there were clinical trial failures for key molecules. Here's a recap of the most notable news highlights from June 2024!
July 2024 Molecule Roundup | 50 Molecules from July to Know
In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.